

ALIMERA SCIENCES INC  
Form 8-K  
April 09, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): April 4, 2019  
ALIMERA SCIENCES, INC.  
(Exact name of registrant as specified in its charter)

|                                                |             |                                   |
|------------------------------------------------|-------------|-----------------------------------|
| Delaware                                       | 001-34703   | 20-0028718                        |
|                                                | (Commission |                                   |
| (State or other Jurisdiction of Incorporation) | File        | (IRS Employer Identification No.) |
|                                                | Number)     |                                   |

|                                          |            |
|------------------------------------------|------------|
| 6120 Windward Parkway                    |            |
| Suite 290                                | 30005      |
| Alpharetta, Georgia                      |            |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01. Other Events.

On April 3, 2019, Alimera Sciences, Inc. (the “Company”) appointed Samer Kaba, MD, as the Company’s Chief Medical Officer, effective April 4, 2019. Dr. Kaba is responsible for directing the Company’s global medical strategy behind current and future projects. Functions under Dr. Kaba’s oversight will include medical affairs, pharmacovigilance, medical information, quality, clinical operations, and regulatory.

On April 4, 2019, the Company issued a press release announcing the appointment of Dr. Kaba as described above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit<br>No. | Description                                                        |
|----------------|--------------------------------------------------------------------|
| 99.1           | <u>Press Release of Alimera Sciences, Inc. dated April 4, 2019</u> |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.

Dated: April 9, 2019 By: /s/ J. Philip Jones

Name: J. Philip Jones

Title: Chief Financial Officer